We are pleased to share the news that Seres Therapeutics has announced that it has received FDA approval for VOWST TM (fecal microbiota spores, live-brpk), formerly SER-109, to prevent the recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI. VOWST is not indicated for the treatment of CDI.
You and your team have played a critical role in bringing VOWST to patients. We sincerely thank you for your efforts and support throughout VOWST’s clinical development journey.
This approval inspires us to continue Seres’ mission of transforming the lives of patients with revolutionary microbiome therapeutics.
On behalf of the VOWST team, thank you again for your dedication to patients with rCDI.
Kind regards,
Jill Colabella, MS